Patent intelligence · US
US 12181485
Methods of blood screening
Methods of blood screening
Patent details — US 12181485
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2024
- Expiration
- Dec 26, 2044
- Applicant
- CASI Pharmaceuticals, Inc
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 12181485 (Methods of blood screening) is held by CASI Pharmaceuticals, Inc. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CASI Pharmaceuticals, Inc
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from CASI Pharmaceuticals, Inc
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12181485?
US 12181485 (Methods of blood screening) is held by CASI Pharmaceuticals, Inc. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12181485?
CASI Pharmaceuticals, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12181485 expire?
Our index shows an expiration date of Dec 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.